Zohydro Abuse-Deterrent Version May Hit Market Faster, Minus Strong Label
This article was originally published in The Pink Sheet Daily
Under pressure from legislators, Zogenix plans to get new version of Zohydro ER that is harder to abuse to market by early 2015, even if won’t have a full set of FDA-approved claims.
You may also be interested in...
FDA reviewed all the categories of pre-marketing and post-marketing data outlined by guidance for abuse-deterrent opioids, but only in vitro and liking studies made it into the updated label.
Endo says label differentiation in the guidance is a positive step; Commissioner Hamburg tells Congress that if new opioid formulations “significantly” deter abuse, generic versions will have to as well.